Recently, Crossject (PA:ALCJ) disclosed the identity of the product behind its L15 program. L15 is its needle-free version of hydrocortisone, which Crossject will develop for the treatment of acute adrenal insufficiency, a potentially fatal condition.
The company expects the commercial launch of the product in H118, although we believe peak sales will be a modest €9m as it is a niche market with little pricing power.
Tackling a potentially fatal condition
Adrenal insufficiency is a condition where a patient is missing certain hormones like cortisol, which helps the body use sugar and protein for energy and helps it recover from stresses and infections. The condition has multiple causes including autoimmune disease, tuberculosis, congenital adrenal hyperplasia (CAH), benign pituitary tumours, brain injury or even over-use of steroids.
To read the entire report, please click on the PDF file below: